Patent classifications
C07C235/62
RESORCINOL-BASED COMPOUNDS AND USES THEREOF
The disclosure provides for resorcinol-based compounds, pharmaceutical compositions made therefrom, and methods of treatment thereof for various disorders, including neoplastic disorders.
COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.
##STR00001##
COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.
##STR00001##
4-membered ring carboxamides used as nematicides
Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides. ##STR00001##
4-membered ring carboxamides used as nematicides
Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides. ##STR00001##
Cannabinoid derivatives
This disclosure relates to cannabinoid derivatives of Formula (I), wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the cannabinoid derivatives. These compounds are potential cannabinoid receptor inhibitors, including CB1 and CB2 receptors.
Cannabinoid derivatives
This disclosure relates to cannabinoid derivatives of Formula (I), wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the cannabinoid derivatives. These compounds are potential cannabinoid receptor inhibitors, including CB1 and CB2 receptors.
Inhibitors of the Wnt/beta-catenin pathway
The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.
Inhibitors of the Wnt/beta-catenin pathway
The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.
4-membered ring carboxamides used as nematicides
Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides. ##STR00001##